Treatment of bioresorbable scaffold failure
EuroIntervention , Volume 11 p. V175- V180
Bioresorbable scaffolds (BRS) are a promising new interventional treatment strategy for coronary artery disease (CAD). They are intended to overcome some of the shortcomings of metal drug-eluting stents (DES), mainly late reinterventions which occur at a consistent rate after one year and have not been reduced by the use of local drug elution. Initial experience in non-complex lesions established efficacy in opening the vessel and the concept of bioresorption. However, with the use of BRS in more complex lesions, the incidence of BRS failure, including both scaffold restenosis and thrombosis, has also increased. Therefore, understanding of both the pathophysiology and of the available treatment options of scaffold failure remains an important issue in ensuring procedural and long-term clinical success.
|Organisation||Department of Cardiology|
Felix, C.M, Everaert, B, Jepson, N, Tamburino, C, & van Geuns, R.J.M. (2015). Treatment of bioresorbable scaffold failure. EuroIntervention, 11, V175–V180. doi:10.4244/EIJV11SVA42